Patent classifications
A61P17/10
Synergistic anti-inflammatory compositions
The present invention is directed to a personal composition comprising a) a strobilurin; b) salicylic acid wherein the ratio of a:b is from about 1:1 to about 100:1; wherein there is a synergistic anti-inflammatory/cellular stress activity.
Antibacterial Treatments Using Cannabinoids
A method for the treatment or prevention of a topical infection by a bacteria of the genus Propionibacterium comprising the step of:
administering a therapeutically effective amount of a topical composition comprising a cannabinoid.
ANTI-ACNE COMPOSITIONS
The present invention relates to a composition, preferably a cosmetic composition, comprising, in an aqueous phase: at least one anti-acne active agent; and hydroxyethylcellulose and at least poly(2-acrylamido 2-methyl propane sulfonic acid),
and uses thereof.
METHOD FOR DECOMPOSING COMPOUND AND COMPOUND
A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:
##STR00001##
wherein R.sup.111, R.sup.121, R.sup.131, and R.sup.141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R.sup.111, R.sup.121, R.sup.131, and R.sup.141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A.sup.101 represents a monovalent organic group; and A.sup.102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.
BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Topical composition
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
NOVEL SKIN CARE COMPOSITION
The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising live bacteria of at least one Cutibacterium acnes (C. acnes) strain in combination with an excipient that specifically supports their viability during storage and/or their ability to replicate after application to the skin. Preferably, the cosmetic or therapeutic skin care composition comprises bacteria of at least one C. acnes strain selected from the group consisting of D1, A5, C1, C3, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1, and F4. The invention also provides a method for treating or preventing acne by applying the skin care composition of the invention to a skin area in need of treatment. The invention also relates to the use of a skin care composition of the invention for treating or preventing acne.
Bactericides and antifungal agents
Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.
Bactericides and antifungal agents
Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.
THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.